A practical synthesis of a novel DPAGT1 Inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies Reagents/tools:
Immunotherapy that targets N-linked glycans has not yet been developed due in large part to the lack of specificity of N-linked glycans between normal and malignant cells. N-Glycan chains are synthesized by the sequential action of glycosyl transferases in the Golgi apparatus. It is an overwhelming task to discover drug-like inhibitors of glycosyl transferases that block the synthesis of specific branching processes in cancer cells, killing tumor cells selectively. It has long been known that N-glycan biosynthesis can be inhibited by disruption of the first committed enzyme, dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (DPAGT1). Selective DPAGT1 inhibitors have the promising therapeutic potential for certain solid cancers that require increased branching of N-linked glycans in their growth progressions. Recently, we discovered that an anti-Clostridium difficile molecule, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) showed DPAGT1 inhibitory activity with the IC 50 value of 0.25 mM. It was confirmed that APPB inhibits N-glycosylation of β-catenin at 2.5 nM concentration. A sharp difference between APPB and tunicamycin was that the hemolytic activity of APPB is significantly attenuated (IC 50 > 200 mM RBC). Water solubility of APPB is >350-times greater than that of tunicamycin (78.8 mg/mL for APPB, <0.2 mg/mL for tunicamycin). A novel DPAGT1 inhibitor, APPB selectively inhibits growth of the solid tumors (e.g. KB, LoVo, SK-OV-3, MDA-MB-432S, HCT116, Panc-1, and AsPC-1) at low mM concentrations, but does not inhibit growth of a leukemia cell (L1210) and the healthy cells (Vero and HPNE) at these concentrations. In vitro metabolic stability using rat liver microsomes indicated that a half-life (t 1/2 ) of APPB is sufficiently long (>60 min) for in vivo studies (PK/PD, safety profiles, and in vivo efficacy) using animal models. We have refined all steps in the previously reported synthesis for APPB for larger-scale. This article summarizes protocols of gram-scale synthesis of APPB and its physicochemical data, and a convenient DPAGT1 assay.
followed by 80% TFA in H 2 O; the crude product was purified by DOWEX 50W x 4 ion exchange resin followed by preparative HPLC to furnish 1 in 88% overall yield (Scheme 1).
General
All chemicals were purchased from commercial sources and used without further purification unless otherwise noted. THF, CH 2 Cl 2 , and DMF were purified via Innovative Technology's Pure-Solve System. All reactions were performed under nitrogen atmosphere. Reactions were monitored by TLC Scheme 1. Synthesis of APPB (1). using 0.25 mm coated commercial silica gel plates (EMD, Silica Gel 60F 254 ). TLC spots were visualized by UV light at 254 nm, or developed with ceric ammonium molybdate or anisaldehyde or copper sulfate or ninhydrin solutions by heating on a hot plate. Reactions were also monitored by using SHIMADZU LCMS-2020 with solvents: A: 0.1% formic acid in water, B: acetonitrile. Flash chromatography was performed with SiliCycle silica gel (Purasil 60 Å, 230-400 Mesh). 1 H NMR spectral data were recorded on 400, and 500 MHz instruments. 13 C NMR spectral data were recorded on 100 and 125 MHz instruments. For all NMR spectra, chemical shifts (dH, dC) were quoted in parts per million (ppm), and J values were quoted in Hz. 1 H and 13 C NMR spectra were calibrated with residual undeuterated solvent (CDCl 3 : dH = 7.26 ppm, dC = 77.16 ppm; CD 3 CN: dH = 1.94 ppm, dC = 1.32 ppm; CD 3 OD: dH = 3.31 ppm, dC = 49.00 ppm; DMSO-d 6 : dH = 2.50 ppm, dC = 39.52 ppm; D 2 O: dH = 4.79 ppm) as an internal reference. The following abbreviations were used to designate the multiplicities: s = singlet, d = doublet, dd = double doublets, t = triplet, q = quartet, quin = quintet, hept = heptet, m = multiplet, br = broad. Infrared (IR) spectra were recorded on a Perkin-Elmer FT1600 spectrometer. HPLC analyses were performed with a Shimadzu LC-20AD HPLC system. HR-MS data were obtained from a Waters Synapt G2-Si (ion mobility mass spectrometer with nanoelectrospray ionization).
Synthetic procedure for 1 3,3-Dimethylpentane-1, 5-diol (16) : The title compound was synthesized according to the reported procedure [1, 3] : TLC (hexanes/EtOAc 20:80) R f = 0.20; IR (thin film) n max = 3317 (br), 2955, 2934, 1676, 1469, 1366, 1030, 1006, 990 2941, 2891, 2866, 1463, 1384, 1366, 1096, 1065, 1012, 995, 881, 745, 678, 656 3,3-Dimethyl-5-((triisopropylsilyl)oxy)pentanoic acid (15): To a stirred solution of 19 (38.8 g, 134.5 mmol) and TEMPO (1.05 g, 6.73 mmol) in MeCN (135 mL) an phosphate buffer (pH = 6.8, 135 mL) were added NaClO 2 (14.6 g, 141.4 mmol) and bleach (8.25%, 65 mL) at 35 C. After being stirred for 4 h, the reaction mixture was extracted with EtOAc and combined organic phase was dried over Na 2 SO 4 and concentrated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 90:10) to give 15 (40.7 g, 134.5 mmol, 100%) as an orange oil: TLC (hexanes/EtOAc 50:50) R f = 0.50; IR (thin film) n max = 2942, 2866, 1705, 1463, 1246, 1097, 996, 881 , 738, 678 cm À1 ; 1 H NMR (400 MHz, CDCl 3 ) d 3.88 (t, J = 5.8 Hz, 2H), 2.38 (s, 2H), 1.71 (t, J = 5.8 Hz, 2H), 1.20-1.11 (m, 3H), 1.09 (s, 12H), 1.08 (s, 6H), 1.07 (s, 6H); 13 C NMR (101 MHz, CDCl 3 ) d 173. 9, 60.7, 46.8, 42.6, 32.4, 28.5 (2C) 50, 169.63, 169.42, 138.80, 134.18 (2C), 129.81 (2C), 127.45, 87.95, 79.97, 73.67, 71.41, 63.46, 21.15, 20.75, 20.53 (2R,3S,4S,5S)-2-(Hydroxymethyl)-5-(p-tolylthio)tetrahydrofuran-3,4-diyl diacetate (12): To a stirred solution of 10 (24.3 g, 62.8 mmol) in MeOH/THF (4:1, 300 mL) was added [ t Bu 2 Sn(OH)Cl] 2 (0.72 g, 1.26 mmol). After 20 h at rt, all volatiles were evaporated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 67:33) to provide 11 (17.9 g, 52.7 mmol, 83%): TLC (hexanes/EtOAc 60:40) R f = 0.40; [α] 21 D À0.298 (c = 1.37, CHCl 3 ); IR (thin film) n max = 3484 (br), 3021, 2924, 2877, 1746, 1493, 1432, 1373, 1239, 1222, 1102, 1093, 1046, 1017, 810 89, 169.39, 138.92, 133.88 (2C), 129.93 (2C), 127.45, 87.76, 83.46, 73.89, 71.40, 62.08, 21.17, 20.62, 20.57 (13): To a stirred solution of 12 (17.9 g, 52.7 mmol) and PPh 3 (27.6 g, 105.1 mmol) in dry toluene (100 mL) were added HN 3 (1.0 M in toluene, 262.9 mL, 262.9 mmol) and DIAD (20.7 mL, 105.1 mmol). The reaction mixture was stirred for 8 h at rt, and concentrated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 80:20 to 70:30) to afford 13 (19.0 g, 52.0 mmol, 99%): TLC (hexanes/EtOAc 75:25) R f = 0.40; [α] 21 D À0.899 (c = 3.93, CHCl 3 ); IR (thin film) n max = 3023, 2924, 2101, 1746, 1493, 1436, 1372, 1233, 1217, 1094, 1064, 1044, 1016, 965, 899, 810 60, 88.27, 80.97, 73.74, 71.73, 52.46, 21.14, 20.50, 20.49 (2R,3R,4S,5S)-2-(Azidomethyl)-5-(p-tolylthio)tetrahydrofuran-3,4-diol (13): To a stirred solution of 13 (19.0 g, 52.0 mmol) in MeOH (200 mL) was added K 2 CO 3 (10.0 g, 72.5 mmol). After being stirred for 30 min, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 70:30 to 50:50) to afford 14 (12.9 g, 45.9 mmol, 88%): TLC (hexanes/ (2R,5S)-2-(Azidomethyl)-5-(p-tolylthio)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (4): To a stirred solution of 14 (12.9 g, 45.9 mmol) and 15 (34.7 g, 114.8 mmol) in CH 2 Cl 2 (231 mL) were added DMAP (1.12 g, 9. 17 mmol) and DIC (18.0 mL, 114.8 mmol) at 0 C. The reaction mixture was stirred for 16 h at rt and concentrated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 95:5) to afford 4 (35.1 g, 41.2 mmol, 90%): TLC (hexanes/EtOAc 90:10) R f = 0.60; [α] 21 D À0.293 (c = 1.39, CHCl 3 ); IR (thin film) n max = 2792, 2892, 2866, 2102, 1745, 1464, 1390, 1367, 1282, 1254, 1219, 1190, 1100, 1071, 1054, 1013, 998, 882, 809, 772, 742, 681 91, 170.54, 138.67, 133.89 (2C), 129.81 (2C), 127.88, 88.58, 81.48, 73.52, 71.70, 60.02, 59.97, 52.70, 46.15, 46.03, 44.64, 44.55, 32.68, 32.60, 27.51, 27.47, 27.38, 21.17, 18 .06 (6C), 18.05 (6C), 11.93 (3C), 11.92 (3C); HRMS (ESI+) m/z calcd for C 44 H 79 N 3 NaO 7 SSi 2 [M+Na] 872.5075, found: 872.5088. (3) 11, 162.08, 159.5, 150.87, 150.85, 141.1, 140.8, 140.30, 140.27, 136.9, 135.4, 135.3, 133.99, 133.95, 133.8, 133.6, 131.2, 129.4, 129.3, 128.41, 128.39, 126.4, 126.21, 126.18, 125.5, 125.4, 115.34, 115.32, 114.3, 114.2, 101.8, 101.7, 96.7, 96.4, 89.23, 89.19, 86.8, 86.7, 84.1, 84.0, 80.9, 69.5, 63.02, 62.99, 55.7, 34.72, 34.70, 27.2, 25.3, 20.87, 20.85 [3,4-d] [1, 3] dioxol-4-yl)-5-phenylpent-2-yn-1-yl)oxy)tetrahydrofuran-3,4-diyl bis (3,3-dimethyl-5-((triisopropylsilyl) oxy)pentanoate) (5) . To a stirred suspension of 3 (5 g, 6.44 mmol), 4 (6.57 g, 7.73 mmol), MS3A (7.56 g) and SrCO 3 (4.75 g, 32.2 mmol) in CH 2 Cl 2 (260 mL) were added AgBF 4 (0.63 g, 3.22 mmol) and NIS (1.88 g, 8. 37 mmol) at 0 C. After 24 h, the reaction mixture was added Et 3 N (2 mL) and passed through a silica gel pad (hexanes/EtOAc 1:1). The combined organic phase was concentrated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 90:10 to 80:20 to 70:30) to afford 5 (9.19 g, 6.12 mmol, 95%): TLC (hexanes/EtOAc 67:33) R f = 0.70; [α] 21 D +0.100 (c = 2.09, CHCl 3 ); IR (thin film) n max = 2942, 2866, 2102, 1743, 1724, 1675, 1456, 1278, 1218, 1099, 1070, 882 , 772 cm À1 ; 1 H NMR (400 MHz, CDCl 3 ) d 7.54 (dd, J = 23. 1, 8.5 Hz, 1H), 4H), (m, 4H), 6.84 (d, J = 7.3 Hz, 2H), 6.51 (d, J = 3.7 Hz, 1H), 5.71-5.64 (m, 2H), 5.60-5.49 (m, 2H), 5.20-5.16 (m, 3H) , 4.79 (ddd, J = 7.5, 6.5, 3.1 Hz, 1H), 4.64 (td, J = 5.9, 2.6 Hz, 1H), 4.57 (ddt, J = 11.4, 6.3, 1.9 Hz, 1H), 4.28 (dt, J = 6.2, 2.8 Hz, 1H), 4.19 (tt, J = 6.1, 3.0 Hz, 1H), 3.79-3.72 (m, 7H), 3.50 (ddd, J = 13.0, 7.6, 3.3 Hz, 1H), 3.35 (dd, J = 13.0, 3.4 Hz, 1H), 2.83 (t, J = 7.4 Hz, 2H), 2.55 (td, J = 7.4, 1.8 Hz, 2H), 2.29 (t, J = 1.6 Hz, 2H), 2.24 (dd, J = 5.1, 2.1 Hz, 2H), 1.62-1.55 (m, 7H), 1.36 (d, J = 2.0 Hz, 3H), 1.08-1.00 (m, 54H); 13 C NMR (101 MHz, CDCl 3 ) d 175. 6, 171.0, 170.9, 170.71, 170.70, 170.6, 162.2, 162.1, 159.5, 150.8, 150.7, 140.4, 140.19, 140.15, 140.13, 136.92, 136.91, 135.4, 135.3, 133.9, 133.8, 133.7, 131.2, 129.4, 129.3, 128.5 (2C), 128.4 (2C), 126.5, 126.4, 126.2, 126.1, 125.6, 125.5, 115.29, 115.25, 114.23, 114.22, 104.61, 104.55, 101.83, 101.82, 88.8, 88.2, 84.44, 84.35, 83.9, 81.4, 81.3, 80.6, 79.9, 76.5, 75.9, 75.8, 74.1, 71.8, 71.7, 71.4, 70.7, 69.6, 69.5, 68.9, 68.8, 59.97, 59.96, 55.7, 46.2, 46.0, 44.7, 44.6, 34.7, 34.51, 34.49, 32.7, 32.61, 32.57, 28.0, 27.38, 27.35, 27.3, 27.1, 25.34, 25.27, 20.9, 18.1 (12C) , 11.9 (6C); HRMS (ESI+) m/z calcd for C 74 H 106 Cl 4 N 5 O 15 Si 2 [M+H] 1500.5978, found: 1500.5992. [1, 3] dioxol-4-yl)-5-phenylpent-2-yn-1-yl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (22): A suspended solution of 5 (7.03 g, 4.68 mmol), NH 4 Cl (7.50 g, 140.3 mmol) and Zn (9.17 g, 140.3 mmol) in EtOH/H 2 O (9:1, 50 mL) was stirred at 80 C for 12 h and cooled to rt. The precipitates were filtered and the combined organic solution was concentrated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 50:50 to CHCl 3 /MeOH 96:4) to afford the primary amine 22 46, 171.73, 171.39, 170.66, 162.24, 159.45, 150.84, 140.16, 136.82, 135.21, 135.04, 134.04, 133.95, 133.75, 131.18, 131.16, 131.14, 129.40, 129.35, 128.52, 128.43 (2C), 128.40 (2C), 128.37, 126.42, 126.29, 126.16, 125.40, 125.26, 115.30, 115.24, 114.01, 101.82, 89.55, 84.49, 74.87, 70.13, 60.70, 59.93, 55.69, 47.00, 46.16, 45.95, 44.74, 44.64, 42.72, 34.53, 34.51, 32.62, 32.58, 32.33, 29.69, 28.47, 27.38, 27.34, 27.29, 27.03, 25.21, 25.19, 20.92, 18 (2,4-dichlorophenyl) methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro [3,4-d] [1, 3] dioxol-4-yl)-5-phenylpent-2-en-1yl)oxy)tetrahydrofuran-3,4-diyl bis (3,3-dimethyl-5-((triisopropylsilyl) oxy)pentanoate) (6): To a stirred solution of 22 (5.80 g, 3.93 mmol) and quinoline (10 mL) in THF-MeOH (1:1, 200 mL) was added Lindlar catalyst (2.90 g) . H 2 gas was introduced and the reaction mixture was stirred under H 2 atmosphere (1000 psi). After being stirred for 20 h, the reaction mixture was added Lindlar catalyst (2.90 g) . The reaction mixture was stirred for 20 h under H 2 atmosphere (1000 psi) at rt. The solution was filtered through Celite, concentrated in vacuo. The crude mixture was used for the next reaction without purification. To a stirred solution of the crude mixture in CH 2 Cl 2 (40 mL) was Boc 2 O (1.29 g, 5.89 mmol). After being stirred for 12 h at rt, the reaction mixture was quenched with 1N HCl and extracted with EtOAc. The combined organic solution was washed with saturated aq. NaHCO 3 , dried over Na 2 SO 4 and concentrated in vacuo. The crude mixture was passed through a silica gel pad (hexanes/EtOAc 80:20 to 70:30) . to afford 6 (4.71 g, 2.99 mmol, 76%): TLC (hexanes/EtOAc 75:25) R f = 0.40; [α] 21 D À0.015 (c = 0.86, CHCl 3 ); IR (thin film) n max = 3403 (br), 2957, 2941, 2866, 1720, 1675, 1600, 1556, 1507, 1456, 1382, 1367, 1278, 1247, 1218, 1161, 1100, 1071, 1049, 1013, 999, 882 159.38, 155.94, 150.85, 141.06, 136.87, 136.80, 135.57, 135.31, 135.27, 133.86, 133.66, 133.56, 131.23, 131.20, 129.29, 129.27, 128.52, 128.51, 128.37 (2C), 126.16, 126.15, 126.06, 126.03, 125.99, 125.64, 125.52, 125.46, 125.43, 115.24, 115.23, 114.17, 114.11, 84.61, 81.15, 81.03, 79.30, 79.25, 74.72, 74.29, 70.50, 69.81, 59.95, 59.91, 55.66, 55.65, 46.18, 46.17, 45.92, 44.80, 44.79, 41.64, 35.37, 35.34, 32.56, 32.55, 32.52, 32.50, 29.70, 28.34, 27.27, 27.24, 27.22, 27.10, 27.08, 25.25, 18.05 (12C), 17.88, 11.88 tert-Butyl (4-oxo-4-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)amino)butyl) carbamate (21): To a stirred solution of 4-aminobutyric acid (2.50 g, 24.0 mmol) and NaHCO 3 (6.00 g, 72.0 mmol) in THF-H 2 O (1:1, 24 mL) was added Boc 2 O (5.76 g, 26.4 mmol). After being stirred for 8 h at rt, the reaction mixture was quenched with 1N HCl and extracted with CHCl 3 . The combined organic solution was dried over Na 2 SO 4 and concentrated in vacuo. To a stirred solution of the crude mixture, 20 (4.45 g, 12.14 mmol), NaHCO 3 (5.10 g, 60.7 mmol) and Glyceroacetonide-Oxyma (5.54 g, 24.3 mmol) in DMF-H 2 O (9:1, 60 mL), was added EDCI (4.65 g, 24.3 mmol). After being stirred for 13 h at rt, the reaction mixture was quenched with H 2 O and extracted with EtOAc. The combined organic solution was washed with 1N HCl (aq.), saturated NaHCO 3 (aq.), dried over Na 2 SO 4 and concentrated in vacuo. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 33:67 to 20:80) to afford 21 (5.35 g, 9. 71 mmol, 80%) [4]: TLC (hexanes/EtOAc 20:80) R f = 0.30; IR (thin film) n max = 3303 (br), 2931, 1692, 1637, 1613, 1542, 1504, 1465, 1366, 1264, 1238, 1219, 1193, 1159, 1120, 1111, 1036, 918, 841, 827, 772 3.48 (ddt, J = 11.6, 7.6, 3.8 Hz, 2H), 3.20-3.05 (m, 4H), 2.22 (t, J = 7.1 Hz, 2H), 2.18-2.07 (m, 2H), 1.98-1.89 (m, 2H), 1.81 (quin, J = 6.9 Hz, 2H), 1.43 (s, 9H); 13 C NMR (101 MHz, CDCl 3 ) d 172. 31, 157.99, 156.40, 155.72, 155.70, 142.76, 128.90 (2C), 128.56 (2C), 122.52 (3C), 116.76 (3C), 79.32, 72.55, 46.87, 44.10, 43.12, 39.76, 33.69, 30.15, 28.38 (3C), 26.35 ; HRMS (ESI+) m/z calcd for C 28 H 37 F 3 N 3 O 5 [M+H] 552.2685, found: 552.2701. 4-Amino-N-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)butanamide (8): To a stirred solution of 22 (3.81 g, 6.99 mmol) in CH 2 Cl 2 (10 mL) was added TFA (5 mL). The reaction mixture was stirred for 3 h at rt, and all volatile were evaporated in vacuo. The residue was neutralized with aq. NaHCO 3 extracted with CHCl 3 . The combined organic extracts were dried over Na 2 SO 4 and concentrated in vacuo. The crude mixture of 8 was used for next reaction without purification.
(2R,3R,4R,5S)-2-(((tert-Butoxycarbonyl)amino)methyl)-5-(((1S)-1-((3aR,4R,6R,6aR)-6- (3-(((2,6-dichloro-4-methoxyphenyl) (2,4-dichlorophenyl) methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro [3,4-d] [1, 3] dioxol-4-yl)-2,3-dihydroxy-5-phenylpentyl)oxy)tetrahydrofuran-3,4-diyl bis (3,3-dimethyl-5-((triisopropylsilyl) oxy)pentanoate) (23): To a stirred solution of 6 (4.71 g, 2.99 mmol) and lepidine (2.37 mL, 17.9 mmol) in t-BuOH/ THF/H 2 O (1:1:1, 180 mL) were added K 2 CO 3 (2.06 g, 14.9 mmol), K 3 Fe(CN) 6 (4.91 g, 14.9 mmol) and K 2 OsO 4 Á2H 2 O (1.10 g, 2.99 mmol) at rt. After being stirred for 12 h, the reaction mixture were added K 2 CO 3 (2.06 g, 14.9 mmol), K 3 Fe(CN) 6 (4.91 g, 14.9 mmol) and K 2 OsO 4 Á2H 2 O (1.10 g, 2.99 mmol). After 20 h, the reaction mixture was diluted with EtOAc and quenched with saturated aq. Na 2 SO 3 . The heterogeneous mixture was stirred for 30 min, and extracted with EtOAc. The combined organic solution was washed with 1N HCl, saturated aq. NaHCO 3 , dried over Na 2 SO 4 , and concentrated in vacuo. The crude mixture was passed through a silica gel pad (hexanes/EtOAc 75:25 to 50:50) to afford 23 (3.76 g, 2.33 mmol, 78%) as diastereomeric mixture. This mixture was used for next reaction without further purification. Data for less-polar diastereomer: TLC (hexanes/EtOAc 67:33) R f = 0.30; [α] 22 D 0.210 (c = 1.62, CHCl 3 ); IR (thin film) n max = 3444 (br), 2941, 2866, 1741, 1719, 1675, 1600, 1556, 1457, 1382, 1367, 1278, 1249, 1216, 1160, 1098, 1070, 1049, 1013, 998, 882, 867, 754, 681 7.52 (dd, J = 8.4, 3.6 Hz, 1H), 7.31 (d, J = 2.0 Hz, 2H), 2H), 6H), 6.85 (d, J = 3.4 Hz, 2H), 6.50 (d, J = 5.9 Hz, 1H), 5.75 (dd, J = 17.6, 8.0 Hz, 1H), 5.63 (d, J = 22.1 Hz, 1H), 2H), 5.48 (d, J = 9.7 Hz, 1H), 5.21 (q, J = 7.3, 6.2 Hz, 2H), 5.11 (d, J = 6.8 Hz, 1H), 5.01 (dd, J = 8.4, 4.7 Hz, 1H), 2H), 4.25 (d, J = 5.6 Hz, 1H), 4.16 (dt, J = 8.6, 4.4 Hz, 1H) (m, 6H), 0.86 (dtd, J = 9.1, 6.6, 2.2 Hz, 3H); 13 C NMR (101 MHz, CDCl 3 ) d 170. 85, 170.74, 170.70, 170.70, 150 Â 20 mm) , solvents: 80:20 MeOH:0.05M NH 4 HCO 3 in H 2 O, flow rate: 6.0 mL/min, UV: 254 nm, retention time: 14 min] to afford 1 (1.05 g, 1.19 mmol, 88%): TLC (n-butanol/ethanol/CHCl 3 /28% aqueous ammonia 4:7:2:7) R f = 0.50; [α] 21 D +0.375 (c = 0.30, methanol); IR (thin film) n max = 3352 (br), 2932, 1677, 1505, 1243, 1201, 1136, 801, 722 6, 166.2, 157.6, 152.0, 142.6, 131.2, 129 .6 (2C), 123.6 (2C), 118.11 (2C), 118.07 (2C), 110. 5, 102.7, 92.3, 85.3, 81.4, 80.4, 76.5, 75.1, 74.1 (2C), 73.0, 71.3, 64.4, 43.7, 43.6, 34.7, 31.5, 26.9 ; HRMS (ESI+) m/z calcd for C 39 H 51 F 3 N 7 O 13 [M+H] 882.3497, found: 882.3512 (Fig. 1) .
Preparation of HCl salt of 1
To a stirred solution of 1 (1.05 g, 1.19 mmol) in MeOH (50 mL) was added ice cold 1N HCl (23.8 mL, 23.8 mmol) dropwise. After being stirred for 1 h at rt, the solution was concentrated under reduced pressure and the resultant aqueous solution was lyophilized to give 1HCl salt (Fig. 2) .
Determination of solubility of 1HCl in 0.9% NaCl (saline)
A suspension of 1HCl (4.0 mg) in 0.9% NaCl (30 mL) was stirred for 24 h, and the precipitate was separated by centrifugation at 10,000 Â g for 5 min. The upper solution (1 mL) was analyzed via C18 reverse-phase HPLC [column: Kinetex (100 Å, 5 mm, 250 Â 4.60 mm), solvents: 70:30 MeOH: 0.05 M NH 4 HCO 3 aq., flow rate: 0.5 mL/min, UV: 254 nm, retention time: 12.0 min]. The area of the peak for 1 was quantified. The concentrations were determined via the HPLC intensity-concentration curves [7] [8] [9] .
Determination of solubility of 1HCl in PBS (pH7.4) buffer A suspension of 1HCl (3.8 mg) in phosphate buffered saline (pH 7.4, 30 mL) was stirred for 24 h, and the precipitate was separated by centrifugation at 10,000 Â g for 5 min. The upper solution (1 mL) was analyzed via C18 reverse-phase HPLC [column: Kinetex (100 Å, 5 mm, 250 Â 4.60 mm), solvents: 70:30 MeOH:0.05 M NH 4 HCO 3 aq., flow rate: 0.5 mL/min, UV: 254 nm, retention time: 12.0 min]. The area of the peak for 1 was quantified. The concentrations were determined via the HPLC intensityconcentration curves [7] [8] [9] (Fig. 3) . 
Microsomal stability
Pooled Sprague-Dawley rat liver microsomes were purchased from Corning Life Sciences (Oneonta, NY, USA). Microsomes (20 mg/mL) were thawed on ice and diluted with PBS, potassium phosphate buffer (100 mM, pH: 7.4) at a 1:8 ratio in 1.5 mL Eppendorf tubes. Stock solutions of 1HCl and verapamil (positive control) were made by diluting 10 mg/mL solutions. From the drug stock solution, 10 mL was diluted with 390 mL of buffer (0.1 mg/400 mL). The diluted microsomes (390 mL) were reacted with 10 mL of the diluted drug solution and allowed to equilibrate for 5 min while shaking at 440 rpm. NADPH (10 mg/200 mL; 1000Â drug concentration) was used as a co-factor for this reaction, and 100 mL was added to the solution after equilibration. Ice cold methanol (200 mL) was used to quench the reaction mixture (50 mL aliquots) at 0, 5, 10, 20, 30, 45 and 60 min. The samples containing methanol was lyophilized to remove all volatiles. The residue was dissolved in 1N HCl aq. (10 mL) and MeOH (40 mL). The resulting solution (20 mL) was injected to LC-MS. MS solvent 90:10 acetonitrile/ 0.05% formic acid in water. Flow rate: 0.5 mL/min (Fig. 4) .
DPAGT1 assay
The enzymatic substrate, UDP-Glucosamine-C 6 -FITC was chemically synthesized according to the reported procedures [10] . DPAGT1 was expressed in suspended Expi293 cells for 36 h. The cells were lysed by drawing through a 26 g needle (10 times) and membrane protein was extracted using buffer containing 1% DM (decyl β-D-maltopyranoside) detergent. DPAGT1 was purified using HA (hemagglutinin)-agarose resin and a superdex 200 size exclusion column ( Fig. 5 ).
UDP-Glucosamine-C 6 -FITC (2 mM stock solution, 0.56 mL), MgCl 2 (0.5 M, 4 mL), β-mercaptoethanol (50 mM, 5 mL), CHAPS (20%, 2.5 mL), Tris buffer (pH 8.0, 50 mM), C 55 -dolichyl phosphate (4 mM, 1.68 mL), and 1HCl (0-50 mg/mL in Tris buffer) were place in a 500 mL Eppendorf tube. To a stirred reaction mixture, DPAGT1 solution (10 mL) was added (total volume of reaction mixture: 50 mL adjust with Tris buffer). The reaction mixture was incubated for 4 h at 37 C and quenched with n-butanol (150 mL). Two phases were mixed via vortex and centrifuged at 10,000 Â g for 3 min. The upper organic phase was assayed via reverse-phase HPLC. The organic phase (30 mL) was injected into HPLC (solvent: gradient elution of 85:15-95:5 MeOH/0.05 M aq. NH 4 HCO 3 over 20 min; UV: 485 nm; flow rate: 0.5 mL/min; column: Kinetex 5 mm C8, 100 Å, 150 Â 4.60 mm), and the area of the peak for C 55 -P-Pglucosamine-C 6 -FITC was quantified to obtain the IC 50 value. The IC 50 values were calculated from plots of the percentage product inhibition versus the inhibitor concentration ( Fig. 6 ).
